PI3K-IN-33

Cat. No.:	HY-147898
CAS No.:	2458163-92-1
Molecular Formula:	$C_{23}H_{21}BrN_6O_2$
Molecular Weight:	493.36
Target:	PI3K; Apoptosis
Pathway:	PI3K/Akt/mTOR; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

PI3K-IN-33 (Compound 6e) is a highly selective PI3K inhibitor with IC_{50} values of 11.73, 6.09 and 11.18 μM for PI3K-α、PI3K-β and PI3K-δ , respectively. PI3K-IN-33 arrests cell cycle at G2/M phase and induces apoptosis. PI3K-IN-33 can be used in leukemia research[1].

IC_{50} & Target	PI3Kβ	PI3Kδ	PI3Kα
	6.09 μM (IC_{50})	11.18 μM (IC_{50})	11.73 μM (IC_{50})

In Vitro

PI3K-IN-33 (Compound 6e) (10 μM, 48 hours) possess potent antiproliferative activity can inhibit proliferation of Leukemia SR cell lines in vitro[1].

PI3K-IN-33 (Compound 6e) induces cell cycle arrest toward the G2-M phase (30.3%) and leads to DNA synthesis and apoptosis[1].

PI3K-IN-33 (Compound 6e) (10 μM, 48 hours) results in apoptotic with 12.13% of cells in the early and latest age[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line:	Leukemia SR cell lines.
Concentration:	10 μM
Incubation Time:	48 hours
Result:	Antiproliferative activity with values of 0.76 μM.

REFERENCES

[1]. Helwa AA, et al. Novel antiproliferative agents bearing morpholinopyrimidine scaffold as PI3K inhibitors and apoptosis inducers; design, synthesis and molecular docking. Bioorg Chem. 2020 Sep;102:104051.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA